JPWO2019213245A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213245A5 JPWO2019213245A5 JP2020561795A JP2020561795A JPWO2019213245A5 JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- accumulated
- composition
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001575 pathological Effects 0.000 claims 14
- 102000013498 tau Proteins Human genes 0.000 claims 10
- 108010026424 tau Proteins Proteins 0.000 claims 10
- 208000000350 Central Nervous System Disease Diseases 0.000 claims 3
- 208000009205 Tinnitus Diseases 0.000 claims 3
- 201000008779 central nervous system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 231100000886 tinnitus Toxicity 0.000 claims 3
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 2
- 206010063602 Exposure to noise Diseases 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 206010036626 Presbyacusis Diseases 0.000 claims 2
- 208000009800 Presbycusis Diseases 0.000 claims 2
- 231100000765 Toxin Toxicity 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 1
- 210000003477 Cochlea Anatomy 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Claims (22)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862666459P | 2018-05-03 | 2018-05-03 | |
US62/666,459 | 2018-05-03 | ||
PCT/US2019/030184 WO2019213245A1 (en) | 2018-05-03 | 2019-05-01 | Methods for reducing accumulated pathologic tau protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021523126A JP2021523126A (en) | 2021-09-02 |
JPWO2019213245A5 true JPWO2019213245A5 (en) | 2022-05-10 |
Family
ID=66530499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020561795A Pending JP2021523126A (en) | 2018-05-03 | 2019-05-01 | How to reduce accumulated pathological Tau protein |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210137861A1 (en) |
EP (1) | EP3787750A1 (en) |
JP (1) | JP2021523126A (en) |
WO (1) | WO2019213245A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2178212C (en) * | 1993-12-21 | 2011-06-14 | Marc Vandermeeren | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
US5488145A (en) | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
CA2505355A1 (en) * | 2002-11-07 | 2004-05-27 | Applied Neurosolutions | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
AU2010289838C1 (en) * | 2009-08-24 | 2014-03-06 | Hough Ear Institute | Methods for treating acute acoustic trauma |
US9289404B2 (en) * | 2011-02-04 | 2016-03-22 | Hough Ear Institute | Methods for treating brain injury |
JP6126531B2 (en) * | 2011-10-03 | 2017-05-10 | 国立研究開発法人国立長寿医療研究センター | Tau aggregation inhibitor |
US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
-
2019
- 2019-05-01 JP JP2020561795A patent/JP2021523126A/en active Pending
- 2019-05-01 US US17/052,093 patent/US20210137861A1/en active Pending
- 2019-05-01 EP EP19723991.6A patent/EP3787750A1/en active Pending
- 2019-05-01 WO PCT/US2019/030184 patent/WO2019213245A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1885350B1 (en) | Formulations and methods for treating amyloidosis | |
JP2002537340A5 (en) | ||
JP2011527339A5 (en) | ||
JP2005504804A5 (en) | ||
JP2007535498A5 (en) | ||
JP2014521641A5 (en) | ||
JP2015523346A5 (en) | ||
JP2019537582A5 (en) | ||
US20230285373A1 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
JP2016512262A (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
JP2020527138A5 (en) | ||
JPWO2019213245A5 (en) | ||
US20230201151A1 (en) | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis | |
JP2018505218A5 (en) | ||
JP2013520475A (en) | Oral lactoferrin in the treatment of severe sepsis | |
JP2016506931A5 (en) | ||
JP2020504154A5 (en) | ||
JP2013507443A5 (en) | ||
Dasenbrook et al. | Anti-inflammatory therapies for cystic fibrosis | |
ES2958414T3 (en) | Topical Ciprofloxacin Compositions | |
KR20220066985A (en) | Method of treating neurodegenerative disorders | |
Wingertzahn et al. | Comparison of nasal tissue concentrations in rabbits following administration of hypotonic and isotonic ciclesonide suspensions | |
Kaji et al. | A side effect of neuraminidase inhibitor in a patient with liver cirrhosis | |
US20240148779A1 (en) | Methods for the treatment of proteinopathies | |
JP7337389B2 (en) | Allergen Action Enhancer Containing Hyaluronic Acid as an Active Ingredient |